Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 5th, 2026

LECO_Weekly-Healthcare-News_10-05-2026Download

Healthcare Weekly News and Deals – Oct 5th, 2026

  1. Smart ring maker Oura has postponed its Nasdaq IPO, which would have raised up to $2.2 billion through the sale of 50 million shares, citing uncertainty in the listing market just eight days after formally launching the process. Oura delayed its planned Nasdaq listing despite what it described as strong demand and a strengthening of the business since the IPO process began. The company launched its plans on September 21 and had intended to raise up to $2.2 billion by selling 50 million shares. CEO Tom Hale said Oura aims to deliver an extraordinary IPO for employees and investors and has “the luxury of choosing our moment.” Oura says it is profitable, with revenue expected to grow 90% year over year in fiscal 2026. It follows Holtec Nuclear’s withdrawal earlier in the month. (Link)
  2. U.S. healthcare technology investor Thoreau has committed $500 million to launch Ortet, a frontier AI lab for health building models that connect patient biology, treatment and healthcare administration. Ortet launched on September 29, 2026 with a $500 million commitment from Thoreau, bringing together former drug industry and technology company researchers. The company plans to use the backing to build computing and data infrastructure, train and deploy health-focused models, and recruit researchers and engineers. Ortet has already secured an initial cluster of graphics processing units, the specialized chips used to train and run AI systems. Rather than targeting a single clinical task, the lab is building models intended to link patient biology, treatment and healthcare administration, making it one of the largest single capital commitments to a healthcare AI company at formation. (Link)
  3. Grindr (NYSE:GRND) has agreed to acquire PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, in a $250 million cash-and-stock deal with up to $70 million of additional performance consideration. Grindr will pay $190 million in cash and $60 million in common stock for PurposeMed, with up to $70 million in further cash tied to Freddie’s 2027 performance and payable in 2028. The transaction is expected to close in the fourth quarter and is Grindr’s first major acquisition since its 2009 founding. CEO George Arison said the healthcare line could become as profitable and as large as the core business, and that building it internally would have taken two to three years. Grindr expects the combined U.S. telehealth and pharmacy business to generate more than $400 in monthly revenue per active patient, implying roughly $240 million of annual revenue at 50,000 patients. (Link)
  4. Inogen (NASD: INGN) has agreed to divest its U.S. oxygen rental business to national home respiratory provider Rotech Healthcare for estimated cash consideration of up to $25 million. Inogen (INGN) signed a definitive agreement to sell specified U.S. oxygen rental assets to Rotech Healthcare for total estimated cash consideration of up to $25 million, with closing expected in the fourth quarter of 2026. The rental business generated $24.3 million of revenue in the first half of 2026, a 9.8% year-over-year decline, and will be presented as discontinued operations beginning in Q3. Inogen expects the transactions to increase both its revenue growth rate and adjusted operating income. Subject to closing, the board approved a $15 million increase to the share repurchase authorization, taking it to $45 million through June 2028. (Link)
  5. Interpace Biosciences (IDXG) has filed terms for a $20 million offering of 3.1 million shares at an assumed $6.47 per share to support a proposed uplisting from OTC to Nasdaq. Interpace Biosciences (IDXG), the Parsippany, New Jersey molecular diagnostics company behind the ThyGeNEXT and ThyraMIR v2 thyroid tests, filed terms on September 25, 2026 for a $20 million deal covering 3.1 million shares at an assumed $6.47; the offering remains unpriced. The raise follows an August reverse stock split announced to support the proposed Nasdaq uplisting. Thyroid test volume rose from 25,200 in 2022 to 36,200 in 2025 and pro forma revenue grew from $20.3 million to $34.8 million, a 19.7% CAGR, after the company stopped accepting PancraGEN specimens in May 2025 following a loss of CMS reimbursement. (Link)
  6. KALA Bio (NASD: KALA) has signed a non-binding letter of intent to acquire 100% of a privately held U.S. telehealth management services organization for approximately $15 million in cash and KALA stock. KALA Bio (KALA) signed the LOI on September 24, 2026 for an MSO supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform operating in all 50 states across GLP-1 weight management, hormone health, longevity and sexual wellness. The target generated roughly $12.7 million of unaudited revenue for the trailing twelve months ended August 2026, over $48 million of sales since its 2023 founding, has served more than 90,000 clients and is described as cash-flow positive. The cash portion would come from existing balance sheet resources, with closing targeted for late 2026 or early 2027. (Link)
  7. SpyGlass Pharma (NASD: SGP) has acquired Advanced Vision Science from Santen for about $13 million in cash. Advanced Vision Science has made intraocular lenses since 1975 and supplies Santen’s Eternity lens in Japan. It also licenses glistening-free hydrophobic acrylic material to Bausch + Lomb for the enVista line. Those supply and license arrangements stay in place. SpyGlass, which is developing a drug-pad lens implanted during cataract surgery for glaucoma, is buying the plant to secure commercial lens supply. (Link)
  8. Shionogi has agreed to acquire Austin-based IntraBio for $2.0 billion, adding the rare-disease therapy AQNEURSA. Shionogi is buying all outstanding shares of IntraBio, an Austin company founded in 2015, for $2.0 billion in upfront cash. IntraBio sells AQNEURSA, approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C and, as of September 18, for ataxia in ataxia-telangiectasia in the United States. The company becomes a subsidiary of Shionogi’s New Jersey unit. Closing is scheduled for November or December, subject to antitrust review. Shionogi bought the RADICAVA ALS franchise in April. (Link)
  9. AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics (NASD: SMMT), taking about a 12 percent stake. AstraZeneca is buying convertible preferred equal to about 12 percent of Summit’s common stock, or 10.6 percent fully diluted. The stake sits alongside a clinical collaboration testing AstraZeneca’s Claudin-18.2 antibody-drug conjugate, sonesitatug vedotin, with Summit’s PD-1/VEGF bispecific ivonescimab in gastrointestinal cancers. Each company keeps rights to its own drug. The investment was announced September 29 and was expected to close within about a week. (Link)
  10. GE HealthCare (NASD: GEHC) has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE is a U.S. contract manufacturer for PET radiopharmaceuticals, with 15 sites, 21 cyclotrons and a theranostics development site, plus U.S. rights to FAPI-74, a Phase III PET tracer aimed at pan-cancer imaging. The business will sit in GE HealthCare’s pharmaceutical diagnostics segment and gives the buyer a last-mile network for short-lived tracers. Closing is aimed at the first half of 2027, subject to regulatory approval. (Link)
  11. Lantern Pharma (NASD: LTRN) has agreed to sell 3,669,725 shares at $1.09 in a registered direct offering raising approximately $4 million, with up to $4 million more available from concurrent private placement warrants. Lantern Pharma (LTRN), a clinical-stage AI-native precision oncology company, entered a definitive agreement for a registered direct offering of 3,669,725 shares, or pre-funded warrants in lieu, priced at $1.09 each. Aggregate gross proceeds are expected to be about $4 million. In a concurrent private placement, investors receive unregistered warrants over an equal number of shares at a $1.09 exercise price, exercisable only after stockholder approval and expiring five years later; full cash exercise would add roughly $4 million. Closing was expected on or about September 30, 2026, with proceeds earmarked for working capital and general corporate purposes. (Link)
  12. Leica Biosystems, a Danaher (NYSE: DHR) company, has completed its acquisition of pre-analytical consumables maker StatLab Medical Products from private equity owners Linden Capital Partners and Audax Private Equity. Danaher (DHR) subsidiary Leica Biosystems completed its purchase of privately held StatLab Medical Products on September 28, 2026, acquiring the business from Linden Capital Partners and Audax Private Equity. Terms were not disclosed. The deal extends Leica’s end-to-end anatomic pathology portfolio across specimen collection and preparation, advanced staining, digital imaging and AI-enabled diagnosis. Management positioned the combination as a response to laboratories facing rising case volumes, increasing complexity and staffing pressure, and as support for Leica’s biopharma partnerships within Danaher’s connected diagnostics ecosystem. (Link)
  13. Goldman Sachs (NYSE: GS) and Charlesbank Capital Partners-backed MyEyeDr. has agreed to acquire the 300-plus office optometry division of Partners Group (SWX: PGHN)-owned EyeCare Partners for an undisclosed sum. MyEyeDr., backed by Goldman Sachs (GS) and Charlesbank Capital Partners, is buying EyeCare Partners’ optometry division, which spans more than 300 offices under the Clarkson Eyecare, EyeCare Associates, EyeCare Center, Nationwide Vision and The Eye Doctors brands. Partners Group (PGHN) acquired EyeCare Partners in a $2.2 billion deal in late 2019, while Goldman Sachs bought MyEyeDr. for $2.7 billion the same year; MyEyeDr. already runs roughly 1,000 locations across about 30 states. EyeCare Partners will apply proceeds to reduce debt and strengthen liquidity while focusing on ophthalmology and ambulatory surgical centers. Closing is expected in Q4 2026. (Link 1) (Link 2)
  14. APM Group has agreed to acquire occupational health provider Medcor, combining it with previously acquired WorkCare and its Assure employee assistance business into a 2,000-employee North American platform. APM Group announced on September 28 that it entered an agreement to acquire Medcor, subject to Federal Trade Commission approval, with financial terms and completion date undisclosed. The deal follows APM’s April acquisition of WorkCare. Combined with Assure, the three businesses would employ more than 2,000 people across 450 sites, with services in every U.S. state and territory and every Canadian province. The combined portfolio spans injury prevention, onsite medical services, occupational health screenings, injury triage, telehealth, case management, return-to-work support and mental health services. Medcor, founded in 1984, adds mobile occupational health and 24/7 telehealth. (Link)
  15. Flexpoint Ford has sold behavioral health pharmacy platform ArtesRx — a business it co-founded in 2023 with Dom Meffe — to healthcare specialist Linden Capital Partners. Flexpoint Ford announced the sale of ArtesRx to Linden Capital Partners for undisclosed terms, a sponsor-to-sponsor exit of a platform Flexpoint built from scratch just three years ago. ArtesRx, established in 2023 by Flexpoint and Dom Meffe, is a behavioral health pharmacy platform serving individuals who depend on complex medication regimens. Chicago-based Flexpoint, founded in 2005, writes $50 million to $500 million per transaction across minority and majority structures in both private and public companies. Linden, also Chicago-based and founded in 2004, invests exclusively in healthcare across services, products and distribution and prefers larger cheques. (Link)
  16. Charlesbank Capital Partners and Warburg Pincus-backed MB2 Dental has partnered with Honolulu-based Hawaii Pacific Dental Group in its 14th acquisition of 2026. MB2 Dental, the Dallas dental support organization backed by middle-market private equity firm Charlesbank Capital Partners and growth equity investor Warburg Pincus, formed a strategic partnership with Hawaii Pacific Dental Group. The Honolulu practice, led by Dr. Rohinton J. Patel, provides cosmetic, restorative, preventative and family dentistry. MB2 supports a nationwide network of more than 1,900 affiliated physicians and practice partners across general dentistry, orthodontics, cosmetic care and oral surgery. The transaction expands MB2’s footprint across Hawaii and the broader Pacific region and marks its 14th acquisition of 2026. Financial terms of the private transaction were not disclosed. Link (Link)
  17. Standard Dental Labs (OTCQB: TUTH) has acquired substantially all operating assets of Dr. Tooth, LLC — also known as Sheen Dental Laboratory and Hansen Incarnati — in a cash-and-stock asset purchase with earnout conditions. Standard Dental Labs (TUTH) closed the acquisition effective October 2, 2026, structured as an asset purchase combining cash and SDL common stock with performance conditions tied to retained customer revenue. Management estimates the acquired business adds just over $800,000 in annualized revenue, taking SDL’s estimated annualized base above $1.6 million and nearly doubling the prior estimate. SDL plans to move production to its Sarasota facility, reshoring work currently outsourced to China to lift utilization and facility profitability. Management believes the business can be rebuilt to more than $1.1 million in annualized revenue. (Link)
  18. Banner Capital, with healthcare private equity firm Seventeen Capital as strategic co-investor, has agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, forming medical device manufacturing platform Seaway Group under Executive Chairman Ron Labrum. Salt Lake City-based Banner Capital formed Seaway Group and entered a definitive agreement to acquire the three medical device contract manufacturers, with closing expected in the fourth quarter of 2026. Seventeen Capital, a healthcare private equity firm led by medical device executive Ron Labrum, is a strategic co-investor, and Labrum becomes Executive Chairman at close. Seaway Group is the third platform in Banner Capital Fund II, after Western Pavement Services and Roof Restoration Group. Banner targets founder-led Western U.S. businesses with $4 million to $15 million of EBITDA and managed $611 million as of June 30, 2026. (Link)
  19. Wandercraft has acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (NASD: CHRN), uniting two medical exoskeleton pioneers into a global robotic mobility platform. Wandercraft acquired Ekso Bionics from a ChronoScale Holdings (CHRN) subsidiary in a transaction unanimously approved by both boards and signed and closed simultaneously; financial terms were not disclosed. The combination pairs Wandercraft’s advanced robotics, physical AI and EMEA leadership with Ekso’s U.S. presence, clinical evidence base and commercial reach. Atalante X and EksoNR support patients at more than 700 rehabilitation centers worldwide, with FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, while Eve and Indego Personal address at-home mobility. Wandercraft will continue supporting all four products. (Link)
  20. The University of Kansas Health System has agreed to take full ownership of the St. Francis campus in Topeka from Ardent Health (NYSE: ARDT). The two have run St. Francis and affiliated Topeka sites as a joint venture since 2017, after the campus had been facing closure. Ardent has handled day-to-day operations. KU Health System has provided clinical and financial support. Ardent will stay involved for a period after closing. The transfer is expected by the end of 2026, subject to approvals. (Link)
  21. Biospring Partners has led a growth investment in CDMO Serán Bioscience alongside existing investors Vivo Capital and Bain Capital Life Sciences to fund a new commercial spray-drying facility in Bend, Oregon. Biospring Partners led the growth investment with continued participation from Vivo Capital, Bain Capital Life Sciences and Serán’s executive leadership. Proceeds support a greenfield commercial manufacturing facility on track for completion in Q3 2027, creating an integrated 200,000-plus square foot campus with OEB4 manufacturing, spray drying, nano-milling and finished-dose capabilities. Biospring, founded in 2020, is a healthcare growth buyout firm with more than $500 million under management focused on pharma services; Vivo manages roughly $5.8 billion. Serán employs over 200 people and plans up to 150 additional hires. (Link)
  22. Renovus Capital Partners portfolio company TJP has acquired life sciences market research firm Evolution Consulting & Research, completing an end-to-end research, strategy, creative, pull-through and analytics platform for pharma clients. TJP, a Conshohocken, Pennsylvania value and patient access agency owned by Renovus Capital Partners, acquired Evolution Consulting & Research. The add-on follows TJP’s earlier purchase of FX2 Virtual and gives clients continuity from upfront market research through strategy, creative, virtual field execution and analytics. CEO Rino Mariconda, also an operating partner at Renovus, said the deal fulfills the firm’s vision of a unified platform. Renovus, founded in 2010, invests in knowledge and talent industries including healthcare and life sciences services, and builds platforms through operational improvement and add-on acquisitions. Terms were undisclosed. (Link)
  23. Resonant Clinical Solutions has acquired Hamburg-based labfish rental solutions GmbH and its U.S. and U.K. affiliates, expanding its Equipment & Ancillaries business across Europe. Resonant Clinical Solutions, a Leesburg, Virginia clinical supply chain and sample lifecycle partner, acquired Labfish together with its U.S. and U.K. affiliates for undisclosed terms. Labfish rents scales, freezers, refrigerators, infusion pumps and monitors, supplies kitting and ancillaries, and operates one of the largest in-house calibration facilities serving clinical trials in Europe. It also provides Importer and Exporter of Record services and direct-to-patient logistics, working with partner depots in Argentina, Israel, Turkey and China to supply sites in more than 70 countries. Resonant has over 850 employees and has supported more than 2,500 clinical trials. (Link)
  24. Sheridan Capital Partners has acquired Durham, North Carolina-based single-use bioprocessing components supplier Carolina Components Group, its fourth platform acquisition of 2026. Chicago healthcare private equity firm Sheridan Capital Partners acquired Carolina Components Group, a 2020-founded supplier of ultra-pure components, custom-engineered single-use assemblies and process solutions serving more than 250 biopharmaceutical and contract manufacturing customers. CCG operates over 100,000 square feet of ISO Class 7 and Class 8 cleanroom and manufacturing space, scale Sheridan says regional competitors lack. Sheridan cited CCG’s supplier-agnostic model and its status as a founder-owned business at a growth inflection point. The deal is Sheridan’s fourth of 2026 after ICANotes, Tres Health and PtEverywhere. (Link)
  25. Chicago Pacific Founders has exited veterinary AI company CoVetAI following its acquisition by IDEXX Laboratories (NASD: IDXX), the first realization from CPF’s Pet Fund – Off Leash Capital. IDEXX Laboratories (IDXX) acquired CoVetAI, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, handing Chicago Pacific Founders the first realization from its specialist animal health fund. Financial terms were not disclosed. CPF was CoVet’s sole institutional investor and backed the company from an early stage; Pet Fund partner Gina Del Vecchio described IDEXX as the ideal owner to scale the product globally. The fund closed on September 16, 2026, holds six portfolio investments, and targets a companion animal market currently worth $288.4 billion and projected to reach $560.7 billion by 2034. (Link)
  26. Brady (NYSE: BRC) has sold its French first-aid business Securimed to Safe Life for about $59 million. Securimed, based in Cappelle-la-Grande, sells customized first-aid kits, protective equipment and emergency-response products, mostly to corporate health and safety departments in France. Brady bought the business in 2010. The price is about €53 million. Brady is an identification and safety-products company based in Milwaukee and is treating the unit as outside that core. (Link)

Venture Deals and Other

  1. Anthropic, PBC has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, with share count and price not yet set. Anthropic, PBC confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of its common stock. The submission gives the AI developer the option to go public once the SEC completes its review, with any offering dependent on market conditions and other factors. The number of shares to be offered and the price have not yet been set. The announcement was published under Rule 135 of the Securities Act of 1933 and is not an offer to sell or a solicitation of an offer to buy securities. No valuation, timetable, exchange or selling shareholders were disclosed. (Link 1) (Link 2)
  2. Lux Capital and Natural Capital have co-led a $251 million Series D in El Segundo-based in-orbit pharmaceutical processing company Varda Space Industries, joined by Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital, at a $1.6 billion valuation. Lux Capital and Natural Capital led Varda Space Industries’ $251 million Series D, with Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital participating. The round values the microgravity-enabled life sciences company at $1.6 billion and lifts total capital raised to $598 million. Varda has completed six reentry missions since 2023, with more than a dozen launches and reentries planned through 2028. Proceeds will increase flight cadence and deepen pharmaceutical partnerships toward the first medicine manufactured in space. (Link)
  3. B Capital has led a $33 million Series B in Austin-based microbiome testing company Tiny Health, joined by Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital led Tiny Health’s oversubscribed $33 million Series B, bringing total funding to $46 million. Existing backers Spero Ventures, The Venture City and Overwater Ventures participated alongside new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital manages more than $12 billion and takes a board seat through Senior Principal Nick Whitehead. Proceeds fund clinical research, practitioner education, the Powered by Tiny B2B platform and TinyAI, trained on nearly 200,000 microbiome profiles. Tiny Health also committed $5 million to a Microbiome Research Program. (Link)
  4. Canvas Ventures has led an oversubscribed $10 million Series A in San Francisco-based healthcare AI company Parakeet Health, with Blank Space Ventures, StoryHouse Ventures and HMC INQ participating. Canvas Ventures led Parakeet Health’s oversubscribed $10 million Series A, taking total funding to $13 million. The raise follows 10x annual recurring revenue growth over the past year. Parakeet’s platform manages inbound calls, proactive outreach, fax processing and web scheduling, and now serves six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers across 1,100-plus locations. Canvas co-founder Rebecca Lynn cited the team’s ability to win major healthcare customers and deliver measurable ROI. Parakeet charges on a performance basis tied to verified results. Link (Link)
  5. Biotia has raised an oversubscribed $9 million financing from Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, alongside VillageMD co-founders Tim Barry and Clive Fields. New York clinical metagenomics company Biotia closed an oversubscribed $9 million round that exceeds its previously announced Series A. Investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, plus VillageMD co-founders Tim Barry and Clive Fields. DigitalDx Ventures CEO Michele Colucci becomes board chair and Barry joins the board. Capital will scale Biotia’s New York laboratory, launch further women’s health diagnostics and expand into orthopedics. Its BIOTIA-ID urine test reports 97% sensitivity and 99% specificity. (Link)
  6. Cobalt Capital has led an undisclosed Series A in Los Angeles-based predictive movement health company p°Motion, joined by WME Group, Nimble Ventures, Canaan Ventures and Soul Ventures. Cobalt Capital led the Series A financing, building on support from a broader investor group including WME Group, Nimble Ventures, Canaan Ventures, Soul Ventures and strategic investors connected to professional sports, technology and institutional capital. Neither round size nor valuation was disclosed. Founded in 2019, p°Motion applies machine learning to an assessment methodology built on more than 40 years of movement research, and says it can identify certain injury risks up to 18 months before they occur — a company-reported claim without published validation data. Proceeds fund AI and engineering hiring plus commercial expansion into healthcare. (Link)
  7. Advent has led, and Temasek co-led, a $555 million Series G in Medicare Advantage insurer Devoted Health as part of a $1.18 billion financing. Devoted Health closed $555 million of Series G primary funding within a $1.18 billion primary and secondary financing. Advent led with Temasek as co-lead, joined by The Space Between — both independently and alongside Centricus — plus GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz. The same investors committed $622 million for a shareholder tender offer expected to close later in the fourth quarter. Membership has grown from 212,000 in December 2025 to 538,000 by September 2026, and Devoted is entering 342 new counties and five new states. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 30th, 2026

LECO_Weekly-Healthcare-News_3-30-2026Download
  1. Abbott (NYSE: ABT) Completes Acquisition of Exact Sciences (NASDAQ: EXAS) Abbott (NYSE: ABT) has officially finalized its acquisition of Exact Sciences (NASDAQ: EXAS), a move aimed at bolstering its leadership in the cancer diagnostics and screening market. The integration of Exact Sciences’ flagship Cologuard technology into Abbott’s massive global diagnostics portfolio is expected to drive significant revenue growth and expand access to non-invasive screening tools. Investors are monitoring how this multibillion-dollar deal will impact Abbott’s long-term earnings per share. This strategic consolidation highlights the ongoing trend of medical device giants acquiring specialized biotech innovators to maintain a competitive edge in the preventive healthcare sector. (Link)
  2. Merck (NYSE: MRK) to Acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 Per Share in Cash Merck (NYSE: MRK) has entered into a definitive agreement to acquire Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in an all-cash transaction. This acquisition allows Merck to gain control of Terns’ promising pipeline of oncology and metabolic disease treatments, specifically focusing on small-molecule oral therapies. The premium price reflects investor confidence in Terns’ clinical data and the potential for these assets to offset upcoming patent expirations in Merck’s existing portfolio. The deal reinforces Merck’s aggressive M&A strategy to diversify its pipeline through high-value biotech acquisitions that offer immediate technological advantages and long-term market exclusivity. (Link)
  3. Infosys (NYSE: INFY) to Acquire US Firms Optimum Healthcare IT for $465 Million and Stratus for $95 Million Infosys (NYSE: INFY) is significantly expanding its footprint in the United States healthcare sector by acquiring Optimum Healthcare IT for $465 million and Stratus for $95 million. These investments are designed to enhance Infosys’ digital transformation capabilities, specifically within healthcare provider networks and cloud-based medical data management. By bringing these specialized consulting firms under the Infosys umbrella, the company aims to offer more robust, end-to-end IT solutions to American healthcare systems. Investors view this as a strategic deployment of capital to capture the growing demand for digital modernization and data interoperability within the heavily regulated healthcare industry. (Link)
  4. Cencora (NYSE: COR) to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners’ Retina Business Cencora (NYSE: COR), formerly AmerisourceBergen, has announced a deal to acquire the retina-specific business of EyeSouth Partners to expand its Retina Consultants of America (RCA) platform. EyeSouth Partners is backed by Olympus Partners. This acquisition underscores Cencora’s commitment to specialized physician services, particularly in the high-growth ophthalmology sector. By integrating these practices, Cencora enhances its scale in clinical research and specialty distribution, providing a more comprehensive value proposition to manufacturers and patients alike. The investment reflects a broader private equity-style roll-up strategy within the specialty care market, aimed at optimizing operational efficiencies and expanding the company’s geographic reach across the United States. (Link)
  5. Efferent Acquired by Hopper OS via Financial Sponsor GPI Capital Through an LBO Efferent was acquired by Hopper OS on March 24, 2026, through a leveraged buyout (LBO) backed by financial sponsor GPI Capital. This acquisition is intended to integrate Efferent’s specialized technology into Hopper OS’s “intelligent healthcare operating system,” creating a more seamless data environment for providers. GPI Capital’s involvement indicates a strong private equity interest in the healthcare infrastructure space, focusing on companies that can automate clinical workflows. The undisclosed investment will facilitate the scaling of Efferent’s tools, allowing Hopper OS to offer a more robust, AI-enhanced suite of products to its global healthcare clientele. (Link)
  6. HealthTech Solutions Acquired by Health Management Associates via Financial Sponsor BPOC Through an LBO Health Management Associates (HMA) has completed the acquisition of HealthTech Solutions through a leveraged buyout supported by financial sponsor BPOC. The deal, finalized on March 27, 2026, aims to merge HMA’s Medicaid expertise with HealthTech’s advanced technological capabilities. BPOC’s investment highlights the private equity sector’s focus on Medicaid modernization and state-level healthcare IT. By acquiring HealthTech, HMA strengthens its ability to provide technical advisory services to government agencies. The undisclosed transaction is expected to drive growth by enabling HMA to manage complex data systems and improve health outcomes for vulnerable populations through better technology. (Link)
  7. Careflow Receives Growth Investment from Blueprint Equity to Expand Product Platform Careflow has secured an undisclosed amount of development capital from Blueprint Equity as of March 26, 2026. This strategic growth investment is earmarked for the expansion of Careflow’s product platform and the acceleration of its market penetration. Blueprint Equity’s participation marks a significant vote of confidence in Careflow’s software solutions for the healthcare industry. The capital infusion will allow the company to scale its operations and enhance its technological offerings, focusing on improving workflow efficiency for healthcare professionals. This deal exemplifies the active role of private equity in fostering the growth of mid-sized health-tech firms aiming for market leadership. (Link)
  8. Novartis to Acquire Excellergy in Up to $2B Deal to Expand Allergy Pipeline Novartis has agreed to acquire Excellergy, a U.S.-based biotech developing next-generation therapies for allergic diseases, in a deal worth up to $2 billion including milestone payments. The acquisition adds Excellergy’s lead asset, Exl-111, a next-generation anti-IgE antibody currently in early-stage clinical development, designed to deliver faster and more durable suppression of allergic responses. Exl-111 builds on the same biological pathway as Novartis’ blockbuster Xolair but is engineered to improve efficacy, dosing convenience, and overall disease control across multiple IgE-mediated conditions. The transaction is expected to close in the second half of 2026, pending regulatory approvals, further strengthening Novartis’ leadership in immunology and allergy therapeutics. (Link)
  9. PCSI Completes Acquisition of CareStarter and Feedback to Launch PCSIx Innovation Unit PCSI has finalized the acquisition of CareStarter and Feedback, two companies focused on patient engagement and care coordination. These acquisitions serve as the foundation for PCSI’s new innovation unit, PCSIx. The investment aims to bridge the gap between healthcare providers and patients by utilizing CareStarter’s resource platforms and Feedback’s communication tools. By consolidating these technologies, PCSI intends to streamline the patient journey and improve health literacy. This move signals a shift toward integrated, patient-centered care models, with the investor focusing on long-term value through improved patient outcomes and reduced administrative friction in the care delivery process. (Link)
  10. Collectly to Acquire Pledge Health to Accelerate AI Automation in Patient Finance Collectly has announced its acquisition of Pledge Health, a strategic move designed to integrate AI-driven automation into the patient financial experience. The acquisition focuses on streamlining medical billing and transparent pricing, addressing one of the most significant pain points in American healthcare. By combining forces, Collectly and Pledge Health aim to provide patients with clearer financial insights while helping providers increase collection rates through automated workflows. This investment highlights the growing market for fintech solutions within the healthcare sector, where AI is being leveraged to reduce manual errors and improve the overall transparency of healthcare costs. (Link)
  11. Vitality Acquires Ramp Health to Merge AI Behavioral Health and Workplace Safety Vitality has successfully acquired Ramp Health, aiming to create a comprehensive platform that merges AI-powered behavioral health services with workplace safety protocols. This acquisition is part of Vitality’s broader strategy to enhance corporate wellness programs by providing employers with data-driven tools to support employee mental and physical health. The integration of Ramp Health’s expertise allows Vitality to offer more personalized health interventions and preventative safety measures. Investors see this as a timely move, given the increasing corporate focus on employee well-being and the role of AI in delivering scalable health solutions in a professional environment. (Link)
  12. Palm Primary Care Acquires Two Clinics in Azle to Expand Local Access Palm Primary Care has expanded its clinical footprint by acquiring two primary care clinics in Azle, Texas. This investment is part of the company’s localized growth strategy, focusing on increasing access to high-quality primary care in suburban and rural areas. By acquiring established practices, Palm Primary Care can immediately serve an existing patient base while implementing its standardized care models and advanced technology systems. The deal reflects a continuing trend of consolidation in the primary care sector, where larger organizations acquire independent practices to achieve economies of scale and provide more integrated services to the local community. (Link)
  13. HealthDrive Corp Acquires Georgia Long-Term Care Consulting HealthDrive Corp, backed by Cressey & Company, has acquired Georgia Long-Term Care Consulting, expanding its reach into the specialized field of post-acute and long-term care services. This acquisition allows HealthDrive to strengthen its consultancy and on-site clinical service offerings for seniors in long-term care facilities. The investment is driven by growing demand for specialized medical services within the aging population. By integrating the Georgia-based firm, HealthDrive enhances its ability to manage complex care needs and regulatory compliance for long-term care facilities. This move reinforces HealthDrive’s position as a major player in the evolving landscape of senior healthcare services in the United States. (Link)
  14. Cerebral Acquires Inflow to Broaden Mental Health and ADHD Support Cerebral has acquired Inflow, a startup focused on digital tools for ADHD management, to broaden its behavioral health platform. This acquisition enables Cerebral to provide more specialized, non-clinical support for neurodivergent individuals, complementing its existing telepsychiatry services. The investment highlights Cerebral’s strategy to become a holistic provider of mental health solutions by incorporating self-management tools and community support into its clinical model. Investors are watching how this expansion into digital therapeutics will help Cerebral differentiate itself in a crowded telehealth market while improving long-term patient engagement and clinical outcomes for those with ADHD. (Link)
  15. Gilead Sciences to Acquire Ouro Medicines in $2.2B Deal to Expand Autoimmune Pipeline Gilead Sciences announced it will acquire Ouro Medicines in a transaction valued at up to approximately $2.2 billion, including $1.675 billion upfront and potential milestone payments. The deal centers on Ouro’s lead asset, a clinical-stage BCMAxCD3 T-cell engager designed to treat severe autoimmune diseases by targeting pathogenic B cells. Early data has shown promising efficacy and a differentiated safety profile, positioning the therapy as a potential “immune reset” approach. Strategically, the acquisition expands Gilead’s inflammation and immunology pipeline as it seeks to diversify beyond its core HIV franchise. (Link)
  16. RTW Investments Boosts Stake in Cogent Biosciences RTW Investments increased its position in U.S.-based Cogent Biosciences by purchasing over 4.1 million shares, representing an estimated $116 million investment and signaling strong conviction in the company’s pipeline. The stake now accounts for roughly 2.7% of RTW’s reportable assets, highlighting the importance of the position within its biotech-focused portfolio. Cogent is advancing precision therapies for genetically defined diseases, with key U.S. regulatory milestones, including an FDA decision expected in late 2026, acting as major value inflection points. The move reflects continued investor interest in U.S. biotech innovation, particularly companies nearing potential commercialization. (Link)
  17. GeBBS Healthcare Solutions Announces Acquisition of RND OptimizAR GeBBS Healthcare Solutions, Inc., a leading provider of technology-enabled Revenue Cycle Management (RCM) and Risk Adjustment Solutions for healthcare providers and payers, announced this morning the acquisition of RND OptimizAR, an India-based specialized provider of Revenue Cycle Management services focused on the Durable Medical Equipment (DME) and Home Medical Equipment (HME) market. The deal strengthens GeBBS’ capabilities in niche RCM segments. GeBBS is backed by global investors including EQT and ChrysCapital. (Link)
  18. Vision Innovation Partners Acquires Frederick Eye Institute Vision Innovation Partners (VIP), a leading Mid-Atlantic eye care platform with 69 locations and backed by Gryphon Investors, announced this morning the acquisition of Frederick Eye Institute, a comprehensive ophthalmology practice in Frederick, Maryland. This marks VIP’s 28th add-on acquisition since 2017 and further strengthens its presence in the key Maryland. (Link)
  19. AI Maverick Intel Announces LOI to Acquire HEAL Access Canada  The proposed acquisition would integrate HEAL’s AI-powered patient navigation and virtual care coordination platform into its ecosystem. The deal represents the first transaction under its Right of First Refusal agreement with HEAL. (Link)
  20. Monument MicroCap Partners Invests in Champion Wellness Centers to Support Growth and Expansion The investment supports Champion Wellness Centers, a Tampa-based provider of chiropractic and multidisciplinary wellness services. The company operates a network of clinics offering physical therapy, regenerative medicine, and other integrated treatments, positioning it to benefit from growing demand for holistic care. The partnership will support geographic expansion and add-on acquisitions. (Link)

Venture Deals and Other

  1. eMed Raises $200 Million Led by Aon, Including Participation from Tom Brady and Linda Yaccarino to Expand GLP-1 Access eMed has received a strategic investment from a high-profile group including Tom Brady and Linda Yaccarino to support its mission of expanding access to GLP-1 weight-loss medications. The funding will enhance eMed’s digital health platform, which provides clinical oversight and testing for patients seeking metabolic treatments. This investment reflects the massive market demand for weight-loss drugs and the role of telehealth in managing prescription distribution. The involvement of such prominent figures suggests a shift toward celebrity-backed healthcare ventures that aim to combine medical credibility with mass-market consumer appeal in the rapidly growing obesity-treatment sector. (Link)
  2. Adonis Raises $40 Million in Series C Funding to Transform Revenue Cycle Management Adonis has successfully closed a $40 million Series C funding round to accelerate the development of its AI-driven revenue cycle management platform. This significant capital infusion will be used to enhance the company’s automation capabilities, helping healthcare providers reduce administrative burdens and improve billing accuracy. The investment round reflects strong venture capital confidence in Adonis’s ability to solve complex financial inefficiencies within the healthcare system. With this new funding, Adonis plans to expand its engineering team and scale its go-to-market strategies, aiming to become the standard for financial operations in large-scale medical groups and health systems. (Link)
  3. Blossom Health Secures Series A Funding Led by Headline to Expand Telepsychiatry Services Blossom Health has raised a Series A investment round, with Headline serving as the lead investor. The funding is intended to scale Blossom Health’s telehealth and telepsychiatry platform, which focuses on providing accessible mental healthcare to underserved populations. Headline’s involvement brings both capital and strategic expertise in scaling consumer-facing digital health brands. Blossom Health plans to use the funds to hire more clinical staff and enhance its mobile application interface. This deal highlights the continued venture capital appetite for mental health startups that leverage technology to overcome traditional barriers to care, such as cost and geographic location. (Link)
  4. Dimer Health Raises $13.5 Million for AI-Driven Post-Discharge Care Platform Dimer Health has secured $13.5 million in funding to support its AI-driven platform designed to improve post-discharge patient care. The investment will be used to further develop technology that monitors patients after they leave the hospital, aiming to reduce readmission rates and improve recovery outcomes. By utilizing predictive analytics, Dimer Health helps clinicians identify high-risk patients who may need immediate intervention. This venture deal underscores the growing interest in “hospital-at-home” models and the use of artificial intelligence to bridge the gap between acute hospital stays and long-term recovery in a home setting. (Link)
  5. Gimlet Labs Raises $80 Million to Transform AI Inference Infrastructure Gimlet Labs has closed a substantial $80 million funding round aimed at transforming AI inference infrastructure. While not strictly a healthcare firm, its technology is pivotal for the future of AI-driven medical diagnostics and drug discovery. The investment will allow Gimlet Labs to scale its hardware and software solutions that make running complex AI models faster and more cost-effective. Venture capitalists are betting on Gimlet Labs to provide the foundational infrastructure that will power the next generation of AI applications across various sectors. This capital will be used for research and development and expanding their manufacturing capabilities to meet global demand. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Mar 23rd, 2026

LECO_Weekly-Healthcare-News_3-23-2026Download
  1. GE HealthCare (NASD: GEHC) Completes $2.3B Acquisition of Intelerad to Bolster Cloud-First Imaging Solutions GE HealthCare (NASDAQ: GEHC) has finalized its acquisition of Intelerad Medical Systems, a leading provider of enterprise imaging software. This strategic move is designed to accelerate GE HealthCare’s transition toward cloud-based enterprise solutions and “precision care.” By integrating Intelerad’s informatics platform, GE HealthCare aims to improve clinician workflows and data accessibility across hospital systems. The acquisition enhances the company’s digital health portfolio, focusing on scalable, interoperable imaging tools that reduce administrative burdens. This deal reflects the broader industry trend of medical technology giants acquiring software firms to dominate the healthcare data infrastructure market. (Link)
  2. Movano (NASD: MOVE) Completes All-Stock Merger with Corvex (NASD: CVEX) and Rebrands Movano Health (NASDAQ: MOVE) and Corvex have completed a strategic merger, creating a unified entity focused on AI-driven cloud infrastructure for healthcare. Movano, known for its wearable medical technology and the Evie Ring, will leverage Corvex’s cloud capabilities to enhance its data analytics and patient monitoring services. The merger aims to create a “cloud infrastructure powerhouse” capable of processing large-scale health data for clinical and consumer applications. This transaction reflects the merging of hardware and software capabilities in the wearable tech space to provide more comprehensive, actionable health insights through artificial intelligence. (Link)
  3. Knowtion Health Acquires Revly to Enhance RCM and AI-Driven Denial Management Management via its financial sponsors Arsenal Capital Partners, Sunstone Partners and Ardan Equity Knowtion Health, a leader in revenue cycle management (RCM) and claim denial resolution, has acquired Revly, an AI-powered billing technology company. Knowtion Health is a portfolio company of Sunstone Partners. This acquisition integrates Revly’s advanced automation into Knowtion’s existing platforms to help hospitals and health systems recover unpaid claims more efficiently. By combining human expertise with Revly’s AI, Knowtion aims to reduce the rising rate of insurance denials. This deal underscores the high demand for AI-driven solutions in the administrative healthcare space to combat labor shortages and complex payer requirements. (Link)
  4. Prestige Consumer Healthcare (NYSE: PBH) to Acquire Breathe Right from Foundation Consumer Healthcare Prestige Consumer Healthcare Inc. (NYSE: PBH) has signed a definitive agreement to acquire the Breathe Right nasal strip brand from Foundation Consumer Healthcare. This acquisition strengthens Prestige’s portfolio of leading over-the-counter consumer brands, specifically within the respiratory care segment. Breathe Right is the global leader in the nasal strip category, and this move is expected to be immediately accretive to Prestige’s earnings and free cash flow. The deal highlights Prestige’s ongoing strategy of acquiring established, high-growth consumer health brands to leverage its existing retail distribution network and marketing infrastructure. (Link)
  5. Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC (NASD: IAC) An affiliate of Pacific Avenue Capital Partners has completed the acquisition of Care.com from IAC (NASDAQ: IAC). Care.com is the world’s leading platform for finding and managing high-quality family care, including childcare, senior care, and specialized medical care. Under the new ownership of Pacific Avenue, the company plans to invest in product innovation and expand its enterprise offerings for employers. This private equity buyout signifies a shift for Care.com as it moves away from a conglomerate structure to focus on independent growth in the rapidly expanding digital caregiving marketplace. (Link)
  6. Aria Care Partners Acquires Coronado Dental to Expand On-Site Clinical Services in Arizona via its financial sponsor Serent Capital Aria Care Partners, a leading provider of onsite ancillary medical services for skilled nursing facilities, has acquired Coronado Dental. This acquisition marks Aria’s entry into the Arizona market. Aria Care Partners, which is backed by private equity investment, focuses on delivering dental, vision, hearing, and podiatry services directly to residents in long-term care facilities. By acquiring Coronado Dental, Aria expands its footprint and reinforces its position as a dominant player in the specialized geriatric clinical services sector. The deal highlights the consolidation of fragmented ancillary care providers under larger, PE-backed management platforms. (Link)
  7. Blackstone-Backed (NYSE: BX) Chartis Acquires Health Tech Firm Leap AI The Chartis Group, a healthcare advisory and analytics firm backed by Blackstone (NYSE: BX), has acquired Leap AI. Leap AI specializes in healthcare-specific artificial intelligence automation, focusing on streamlining clinical and administrative workflows. This acquisition allows Chartis to integrate advanced AI capabilities into its consulting services, helping hospital systems improve operational efficiency. For Blackstone, this move represents a continued investment in “applied AI” within the healthcare sector, moving beyond general software into tools that solve specific provider pain points. The deal highlights the aggressive expansion of tech-enabled consulting platforms. (Link)
  8. WELL Health (TSX: WELL) Subsidiary WELLSTAR Acquires Two Billing Platforms to Expand National Footprint WELLSTAR, a subsidiary of WELL Health Technologies Corp. (TSX: WELL), has completed the acquisition of two strategic billing and back-office service providers. These acquisitions expand WELL’s national billing platform, which now serves medical professionals across six Canadian provinces. WELL Health continues its “buy-and-build” strategy, acquiring fragmented healthcare IT and billing services to create a unified, tech-enabled provider network. By scaling its billing division, WELL increases its recurring revenue and strengthens its position as the largest owner-operator of outpatient clinics in Canada, providing essential administrative infrastructure to thousands of physicians. (Link)
  9. James River Home Health Acquires Golden Rule Hospice to Expand End-of-Life Care Services James River Home Health and Hospice has completed the acquisition of Golden Rule Hospice. This strategic move expands James River’s service area and strengthens its specialized hospice care offerings. The acquisition is part of James River’s effort to build a comprehensive home-based care network that covers both skilled home health and end-of-life services. As the demand for aging-in-place solutions grows, regional providers like James River are increasingly acquiring boutique hospice agencies to achieve better economies of scale and improve clinical outcomes through standardized care models. (Link)
  10. Loma Linda University Health and Kara Health Form Joint Venture for New Hospice Agency Loma Linda University Health (LLUH) has partnered with Kara Health to launch a joint venture called Loma Linda University Hospice. Kara Health is a tech-enabled home care and hospice provider. This partnership combines LLUH’s clinical excellence with Kara Health’s proprietary technology platform to provide high-quality, data-driven end-of-life care. The joint venture aims to improve patient transitions from the hospital to the home and enhance the palliative care experience through remote monitoring and streamlined communication. This model illustrates the growing trend of health systems partnering with startups to modernize home health. (Link)
  11. Palladium Equity Partners Acquires Majority Stake in DME Express from Waypoint Capital Palladium Equity Partners, LLC has announced its acquisition of a majority interest in DME Express, a leading provider of medical equipment services to the hospice industry. The stake was acquired from Waypoint Capital Partners. DME Express specializes in high-touch delivery and management of durable medical equipment (DME), primarily serving hospice and post-acute care facilities. Palladium’s investment is aimed at accelerating the company’s geographic expansion and enhancing its service capabilities. This transaction underscores the increasing interest from private equity in specialized logistics and equipment providers within the value-based care and end-of-life care sectors. (Link)
  12. SportsMed Physical Therapy Expands to 54 Clinics with New Connecticut Locations SportsMed Physical Therapy, a leading provider of physical therapy, chiropractic, and acupuncture services, has opened two new clinics in Connecticut. These openings bring the company’s total to 54 locations across New Jersey and Connecticut. SportsMed, which has received investment from private equity firms, continues to pursue a rapid “de novo” growth strategy alongside strategic acquisitions. The company focuses on a multidisciplinary approach to musculoskeletal health. This expansion reflects the high investor interest in the physical therapy sector due to its predictable revenue streams and the increasing demand for non-invasive pain management solutions. (Link)
  13. Allina Health to join Sutter Health in $26B proposed transaction in Strategic Realignment Allina Health has released a strategic announcement regarding its long-term operational and investment plan for its Minnesota-based health system. The plan includes a focus on clinical service realignment and infrastructure investment to support high-growth areas like cardiovascular and oncology care. While not a sale of the company, the announcement details strategic capital allocations aimed at improving financial stability and patient access. This news is critical for investors monitoring the financial health of non-profit systems and their shift toward outpatient-focused care models in a challenging economic environment for hospitals. (Link)
  14. Providence Explores Strategic Options Including Sale of Providence Health Plan Providence, one of the largest non-profit health systems in the U.S., has announced it is exploring strategic options for the sale of its Providence Health Plan (PHP) division. PHP is a regional health insurer serving hundreds of thousands of members in Oregon and Washington. This potential divestiture is part of Providence’s effort to shore up its balance sheet and focus resources on its core hospital operations. A sale would likely attract interest from major national insurers or private equity groups seeking a foothold in the Pacific Northwest insurance market. (Link)
  15. Valir Health Expands Senior Care Presence in Oklahoma City Valir Health has announced the acquisition of a prominent senior care facility in Oklahoma City, continuing its expansion in the post-acute care and geriatric services sector. Valir Health provides a range of services including inpatient rehabilitation, hospice care, and billing solutions. This acquisition is part of Valir’s broader strategy to consolidate senior living and rehabilitation services within the Oklahoma region. By integrating this new facility, Valir aims to improve care coordination for the elderly population. The deal reflects a regional trend of mid-sized healthcare companies expanding their physical footprint to meet growing geriatric demand. (Link)

Venture Deals

  1. Unnatural Products Raises $45 Million Series B Led by Nextech Invest and Frazier Life Sciences with participation from Northpond Ventures, Cool Springs Financial, and others to Advance Peptide Therapeutics Unnatural Products (UNP), a biotech firm specializing in macrocyclic peptide therapeutics, has secured $45 million in Series B financing. The round was led by Nextech Invest and Frazier Life Sciences, with participation from Northpond Ventures, Cool Springs Financial, and others. The company uses a platform that combines AI and medicinal chemistry to create “unnatural” macrocycles that can hit difficult-to-target intracellular proteins. The capital will be used to advance its lead oncology programs into the clinic and expand its platform capabilities. This funding highlights continued investor confidence in AI-driven drug discovery platforms targeting previously “undruggable” pathways. (Link)
  2. Conduit Health Raises $17 Million Series A Led by Drive Capital to Expand AI-Powered DME Access Conduit Health has raised $17 million in Series A funding led by Drive Capital. Conduit Health operates an AI-powered platform designed to streamline access to Durable Medical Equipment (DME). The platform connects healthcare providers, payers, and suppliers to automate the ordering and fulfillment process, which is traditionally fragmented and manual. The investment will be used to scale the company’s technology and expand its market presence. This deal underscores the venture capital interest in solving administrative bottlenecks within the home health and medical supply chain using modern software-as-a-service (SaaS) models. (Link)
  3. Verily Secures $300 Million Investment Led by Alphabet (NASDAQ: GOOGL) to Advance Precision Health AI Verily, the life sciences subsidiary of Alphabet (NASDAQ: GOOGL), has secured a $300 million investment to accelerate its precision health AI strategy. This funding round, supported by parent company Alphabet and other institutional investors, will focus on scaling Verily’s data-driven clinical research and care management solutions. The company aims to use the capital to further integrate artificial intelligence into its “Lightship” clinical trial platform and its chronic condition management tools. This massive investment signals Google’s long-term commitment to becoming a dominant player in the convergence of big data, AI, and clinical healthcare. (Link)
  4. Turquoise Health Raises $40 Million Series B Led by Adams Street Partners with participation from Andreessen Horowitz (a16z) and BoxGroup to Power Healthcare Price Transparency Turquoise Health, a healthcare pricing platform, has raised $40 million in Series B funding led by Adams Street Partners, with participation from Andreessen Horowitz (a16z) and BoxGroup. Turquoise Health provides software that enables hospitals and payers to comply with price transparency regulations and manage data-driven contracts. The company intends to use the funds to expand its “ClearContract” platform, which automates the negotiation and management of payer-provider contracts. This investment highlights the growing importance of data transparency tools as healthcare shifts toward value-based care and more complex reimbursement models. (Link)
  5. Condor Software Raises $24 Million Series A Led by Bessemer Venture Partners with participation from Casdin Capital and existing investors for Clinical Trial Finance Management Condor Software has secured $24 million in Series A funding led by Bessemer Venture Partners, with participation from Casdin Capital and existing investors. Condor Software provides a specialized financial management platform for biotech companies to track and manage the complex costs associated with clinical trials. The company aims to replace manual spreadsheets with automated workflows that integrate with clinical and financial data. The new capital will be used to scale its engineering team and accelerate product development, reflecting the niche but high-value demand for fintech solutions tailored specifically to the life sciences industry. (Link)
  6. RAAPID Secures Series A Extension Led by Celesta Capital to Scale Neuro-Symbolic AI for Medical Coding RAAPID has secured a Series A extension funding round led by Celesta Capital to scale its “Neuro-Symbolic” AI-powered medical coding and risk adjustment platform. The company’s technology helps healthcare providers and insurers automate the complex process of clinical documentation and coding, ensuring accurate reimbursement. By combining deep learning with symbolic AI, RAAPID aims to provide higher accuracy and transparency than traditional LLM models. The funding will support geographic expansion and further R&D. This deal illustrates the shift toward specialized, high-accuracy AI tools for administrative healthcare tasks where error margins are critical. (Link)
  7. Health Universe Raises $6 Million Seed Round Led by Eniac Ventures for AI Agents in Medical Workflows Health Universe, a platform for developing and deploying AI “agents” for medical workflows, has raised $6 million in a seed funding round led by Eniac Ventures. The platform allows developers and clinicians to collaborate on AI models that automate specific clinical tasks, such as surgery scheduling or pathology reporting. Health Universe provides the infrastructure for hosting and running these models securely in a compliant environment. This investment highlights the emerging “AI-as-a-Service” model within healthcare, where platforms provide the tools for specialized, agentic AI to be integrated into daily hospital operations. (Link)